Hong Kong stock movement: AB&B BIO-TECH-B rises 18.65%, overseas vaccine cooperation agreement boosts market confidence

Hong Kong Stock Movement AB&B BIO-TECH-B rose 18.65%. Based on recent news, On March 16, AB&B BIO-TECH-B reached an overseas vaccine cooperation agreement with Watson Bio Hong Kong. This news boosted market confidence, driving the stock price up by 18.65%. The vaccine industry has performed strongly recently, and the market reacted positively to the new cooperation agreement. Stocks with High Trading Volume in the Industry Rongchang Bio rose 6.96%. Based on recent news, On March 16, the profit outlook for the innovative drug industry was optimistic, with some leading companies already achieving profitability. It is expected that more companies will enter the profit phase in the next two years, driving stock prices up. Significant net inflows from southbound funds have become an important support for Hong Kong stocks, further boosting market confidence. On March 17, Rongchang Bio announced that it would hold a board meeting on March 27 to review and approve the annual performance for the year ending December 31, 2025, and consider the distribution of dividends. This news enhanced investors' confidence in the company's future performance, driving the stock price up. On March 16, analysts recommended buying Rongchang Bio, with a target price of 97 yuan and a stop-loss level of 83 yuan. This recommendation further attracted investors' attention, driving the stock price up. Net inflows from southbound funds provided strong support for Hong Kong stocks. Sangfor Technologies rose 3.60%. Based on recent key news: On March 17, the government work report listed biomedicine as an emerging pillar industry, with policy catalysts repairing risk appetite in the sector. This policy elevation marks the transition of the pharmaceutical industry from a strategic emerging industry to an emerging pillar industry, indicating that the full-chain policy dividends will continue to be released, driving Sangfor Technologies' stock price up. Source: Zhitong Finance On March 16, net inflows from southbound funds continued to support the Hong Kong stock market. Wind data shows that net inflows from southbound funds have exceeded 180 billion yuan this year, becoming an important support for Hong Kong stocks, aiding in the rise of Sangfor Technologies' stock price. Source: Yicai On March 17, CMB International recommended buying Sangfor Technologies, with a target price of HKD 37.43. The firm expects the industry fundamentals to accelerate positively, recommending buying Sangfor Technologies, further driving the stock price up. Source: Zhitong Finance, with policy dividends in the pharmaceutical industry releasing and funds flowing into Hong Kong stocks. BeiGene rose 1.50%. Based on recent news, On March 17, the power equipment industry is facing new development opportunities against the backdrop of global grid upgrades and growing AI computing power demand. Chinese power equipment companies have competitive advantages in going global due to their ultra-high voltage technology and full industry chain cost advantages, driving related stocks up. On March 16, net inflows from southbound funds continued to support the Hong Kong stock market. Wind data shows that as of March 16, net inflows from southbound funds have exceeded 180 billion yuan this year, with a net inflow scale of 471 billion yuan over the past six months, supporting the Hong Kong stock market On March 15, companies on the Sci-Tech Innovation Board showed an overall trend of increased revenue and reduced losses, with 39 companies reporting a year-on-year revenue growth of 37% for the fiscal year 2025 and a year-on-year reduction in net losses of 57%. The Shanghai Stock Exchange launched measures to optimize refinancing, supporting the refinancing needs of technology innovation companies and boosting market confidence. The funding situation in the Hong Kong stock market remains strong, with accelerated sector rotation. Stocks with High Market Capitalization Rankings in the Industry Innovent Biologics rose by 1.31%. Based on recent key news: On March 17, the government work report listed biomedicine as an emerging pillar industry, with policy catalysts restoring risk appetite in the sector. Innovent Biologics is recommended for purchase, with a target price of HKD 110.62. Source: Zhitong Finance On March 16, southbound capital saw a cumulative net inflow of over RMB 180 billion this year, becoming an important support for the Hong Kong stock market. Innovent Biologics benefits from this capital inflow. Source: Yicai Global On March 17, breakthroughs in AI pharmaceutical technology and the explosion of overseas business development for Chinese innovative drugs formed a dual resonance, accelerating the improvement of the industry's fundamentals. Innovent Biologics is recommended for purchase. Source: CMB International, favorable policies for the pharmaceutical industry, capital inflow into the Hong Kong stock market